🇺🇸 FDA
Patent

US 11236335

Selective antisense compounds and uses thereof

granted A61PA61P25/14A61P25/28

Quick answer

US patent 11236335 (Selective antisense compounds and uses thereof) held by Ionis Pharmaceuticals, Inc. expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Ionis Pharmaceuticals, Inc.
Grant date
Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
24
CPC classes
A61P, A61P25/14, A61P25/28